ALTERITY THERAPEUTICS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0055 AUD | +10.00% |
|
0.00% | -28.57% |
Presenter SpeechTim McGowen (Attendees)Good day, everyone, and welcome back to this Hidden Gem...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Companyâs lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinsonâs disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
Calendar
2025-02-26
- Q2 2025 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -28.57% | 17.37M | |
| +29.77% | 49.18B | |
| +1.00% | 42.11B | |
| +50.47% | 40.37B | |
| -5.26% | 28.85B | |
| +13.68% | 26.09B | |
| -22.99% | 18.71B | |
| +8.22% | 13.26B | |
| +32.41% | 12.32B | |
| -1.62% | 11.99B |
- Stock Market
- Equities
- ATH Stock
- News Alterity Therapeutics Limited
- Transcript : Alterity Therapeutics Limited - Special Call
